Physician profile
Mohammad Qureshi
NPI 1104833326
$5,459.59
in general payments reported to CMS, 2019-2025
36 companies · $1,340 in 2025
The $1,340 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,270 · 2020: $533 · 2021: $84.74 · 2022: $196 · 2023: $374 · 2024: $662 · 2025: $1,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.64 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,104.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $370.19 | 2019-2024 | |
| Lilly USA, LLC | $360.02 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $312.78 | 2022-2025 | Freestyle Libre 3 |
| Chiesi USA, INC. | $300.00 | 2025 | Mycapssa |
| Insulet Corporation | $291.75 | 2019-2025 | Omnipod |
| Amgen INC. | $279.17 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $266.08 | 2019-2025 | |
| Sequel Med Tech, LLC | $227.16 | 2025 | Twiist |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $188.65 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $144.38 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $144.11 | 2019-2020 | |
| Nevro Corp. | $134.94 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $124.70 | 2019 | |
| Corcept Therapeutics | $123.84 | 2020-2025 | Korlym |
| Horizon Therapeutics Plc | $121.46 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $67.54 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Nalpropion Pharmaceuticals LLC | $67.07 | 2019 | |
| Currax Pharmaceuticals LLC | $65.31 | 2019-2020 | |
| Medtronic, INC. | $47.16 | 2023-2025 | Minimed 780g |
| Ascensia Diabetes Care US INC. | $40.43 | 2024-2025 | |
| Medtronic Minimed, INC. | $39.86 | 2019 | |
| Tandem Diabetes Care, INC. | $36.23 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Takeda Pharmaceuticals U.S.A., INC. | $34.17 | 2020 | |
| Radius Health, INC. | $33.89 | 2020 | |
| Shire North American Group INC | $33.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.58 | 2024-2025 | |
| Ibsa Pharma INC. | $18.05 | 2025 | Licart, Flector, Tirosint |
| Dexcom, INC. | $17.80 | 2020 | |
| Esperion Therapeutics, INC. | $17.32 | 2024 | Nexletol |
| Pfizer INC. | $17.13 | 2019 | |
| Companion Medical, INC. | $13.15 | 2019 | |
| Cequr Corporation | $13.11 | 2025 | Cequr Simplicity |
| Lifescan, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.